Left Menu
Development News Edition

EXPLAINER-Making a new generation of 'guided-missile' cancer drugs work


EXPLAINER-Making a new generation of 'guided-missile' cancer drugs work
Representative image

A class of treatments known as antibody-drug conjugates (ADC) combines cancer-tracking proteins with powerful cell toxins. The therapies are getting a fresh start as dozens of drugmakers test a record number of new compounds in people. Nearly 20 years after the first ADC, Pfizer's Mylotarg, was approved, developers say they are now getting a handle on the technology that was long seen as an elegant concept, but one that presented many clinical challenges.

* How do ADCs work? Antibodies such as Roche's top-selling Herceptin have been a mainstay of modern medicine because these immune proteins can be engineered to bind to cancer cells, where they interfere with growth.

With ADCs, drugmakers go a step further and attach cytotoxic molecules to antibodies to destroy the cancer cells outright. Roche's Kadcyla combines Herceptin with the agent mertansine (DM1). The antibodies' role in that combination has been described as that of a Trojan horse, carrying the cytotoxic agent inside the tumor, where it can be deployed.

* What progress has been made in ADC research? So-called "linker" molecules that connect the cell-killing payload to the antibodies have been refined to release the toxins only when the drug is absorbed by a cancer cell.

Some early ADCs fell apart in the bloodstream, leading to failure or unacceptable damage to healthy tissues. Newer ADCs, such as AstraZeneca's and Daiichi Sankyo's Enhertu, have also been designed to kill adjacent tumor cells even after the initially targeted cell has disintegrated.

* How do ADCs stack up against other novel cancer therapy approaches? The so-called CAR-T cell approach, in which patients' own immune system cells are removed from the body and re-engineered to recognize and attack cancer, has been a much bigger focus of pharmaceutical industry investment.

Hundreds of studies are underway from companies like Novartis and Gilead Sciences. Both drugmakers already have therapies on the market that are pegged as potential billion-dollar products in annual sales. But CAR-T cells, for now, are targeted at blood cancers, while ADCs have proven effective against solid tumors. Most CAR-T cells also must be custom made for each patient, requiring huge infrastructure investments, while ADCs can be centrally produced and shipped globally.

ADCs also face competition from another treatment approach called bispecific antibodies. Bispecific are complex therapeutic proteins that can latch onto the body's immune cells and connect them with cancer cells. The number of specifics in the pipelines of drugmakers, including Roche, GlaxoSmithKline, and Bristol-Myers Squibb, is roughly on par with ADCs, according to Beacon Targeted Therapies.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Download The Devdiscourse News App for Latest News.


TRENDING

OPINION/BLOG/INTERVIEW

Future of Food: Technology fostering the road to global food security

Technological innovation can help address most of the pressing issues facing the world today including food security by enhancing productivity, improving financial services, managing resources, addressing environmental concerns, etc....

Conspiracy theories on COVID 19: Legislators, Scientists, and Journalists all joined the Caravan

Conspiracy theories are not new for virus epidemics. There have been conspiracy theories on HIV-AIDS, Polio Vaccines, Ebola Virus, and several other diseases as well. However, what makes the 2019 Novel Coronavirus different from others is ...

Now it’s a war, Uganda deploys army to combat locust swarms

Its for the first time after 1986, the locust swarms have attacked Uganda twice in a season. With the increasing number of countries of Africa under attack by locust swarms, the problem seems to have taken a regional paradigm. Its very diff...

Top 10 Fake News, Myths and Realities on 2019 Novel Coronavirus COVID 19

With nearly 1500 deaths by January 14 and around 65,000 infections in China, the Novel Coronavirus 2019 has become one of the worst health epidemics of the 21st Century. However, 8,573 people have been cured but the rumor mongers are a...

Videos

Latest News

NFLPA to vote on CBA after four-hour meeting

INDIANAPOLIS -- NFL player representatives passed an owner-approved proposed Collective Bargaining Agreement early Wednesday morning, sending the proposal to the full players union for a vote that could create labor peace for 10 years. Beca...

UPDATE 3-Second person dies of coronavirus in France

A second person suffering from the coronavirus died in France overnight as health officials tried to find out how the college teacher, who had not visited any country with a known outbreak, had caught the new disease.The 60-year-old man was...

India''s cultural diversity must be celebrated thru'' enhanced

exchanges Vice Prez Chennai, Feb 26 PTI Vice President M Venkaiah Naiduon Wednesday called for celebration of Indias cultural diversity through enhanced exchanges between people in thecountry. Participating in a function here, he said mutua...

Trump to hold news conference on coronavirus threat to US

President Donald Trump said he will discuss the coronavirus threat at a White House news conference on Wednesday, a day after he sought to minimize fears of the virus spreading widely across the US. Trump tweeted that representatives from t...

Give Feedback